Company news
Precipio, Inc. (NASDAQ:PRPO) news
Every Precipio, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Precipio Announces Q2-2026 Shareholder Update Call
July 31, 2026
Precipio to Present at the Planet MicroCap Las Vegas
June 11, 2026
Precipio Announces Q1 2026 Financial Results
May 14, 2026
Management team’s 2025 market-based Options have vested
May 13, 2026
B2i Digital Welcomes Precipio, Inc. as a New Featured Company
May 11, 2026
Precipio Announces Q1-2026 Shareholder Update Call
May 6, 2026
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
March 12, 2026
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR:...
March 10, 2026
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
February 25, 2026
Precipio Takes Major Steps Toward a Clean Balance Sheet
January 15, 2026
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
December 5, 2025
Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
December 4, 2025
Precipio Announces its Q3-2025 Financial Results
November 14, 2025
Precipio Announces Q3-2025 Shareholder Update Call
November 4, 2025
Precipio Terminates Its ATM
September 2, 2025
Precipio Announces its Q2-2025 Financial Results
August 13, 2025
Precipio Announces Q2-2025 Shareholder Update Call
July 31, 2025
Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
July 11, 2025
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
June 16, 2025
Precipio Announces its Q1-2025 Financial Results
May 14, 2025
Precipio Announces Q1-2025 Shareholder Update Call
May 1, 2025
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
March 17, 2025
Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
February 25, 2025
Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
January 16, 2025
Precipio : Announces Q3 2024 Shareholder Update Call Conference Call to be held on Form 8 K
November 7, 2024
Precipio Announces Q3-2024 Shareholder Update Call
November 6, 2024
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
October 8, 2024
Precipio Announces Employee Stock Option Plan Repricing
September 6, 2024
Precipio Announces Q2-2024 Shareholder Update Call
August 15, 2024
Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
July 25, 2024
Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
July 17, 2024
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
June 13, 2024
Precipio Provides Status Update on Current Business Matters
June 12, 2024
Precipio Secures a short-term $500K Credit Facility
May 6, 2024
Precipio Announces Year end 2023 Shareholder Update Call
March 25, 2024
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
February 13, 2024
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
February 6, 2024
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
January 23, 2024
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
January 17, 2024
Precipio Announces Christina Valauri joins the Board of Directors
January 2, 2024
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
December 14, 2023
Precipio Announces Q3-2023 Shareholder Update Call
November 16, 2023
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
October 18, 2023
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
October 3, 2023
Precipio Continues to Sign New HemeScreen™ Customers
September 28, 2023
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
September 25, 2023
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
September 21, 2023
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
September 13, 2023
Precipio Announces Q2-2023 Shareholder Update Call
August 10, 2023
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
August 8, 2023